• Markets
    • icon
  • Companies
BIT · ASX

Biotron Limited (ASX:BIT)

AU$0.089

 0.0 (0.0%)
ASX:Live
06/12/2023 04:10:05 PM
HALO Ords GROWTH AUS All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

BIT Overview

BIT Health Scores

Short Term

Mean Revision

Trend

Event

Halo Model

MQV

GARP

MQV Small

Valuation

Value

Consensus

Momentum

Price

Earnings

Growth

Earnings

Dividends

Quality

Capital Efficiency

Balance Sheet

About BIT

Website

Biotron Limited

Telephone

61.2.9805.0488

Address

Suite 3.3 56 Delhi Road North Ryde, New South Wales (NSW) 2113

Description

Biotron Ltd. engages in the funding and management of research, development, and commercialization of drugs targeting significant viral diseases. It is developing the compound BIT225 for the treatment of HIV-1. The company was founded in February 1999 and is headquartered in North Ryde, Australia.

BIT Price Chart

Key Stats

Market Cap

AU$84.81M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.02 - 0.12

Trade Value (12mth)

AU$49,039.00

1 week

-9.18%

1 month

-11%

YTD

206.9%

1 year

229.63%

All time high

0.430968

Key Fundamentals

EPS 3 yr Growth

-18.900%

EBITDA Margin

N/A

Operating Cashflow

-$3m

Free Cash Flow Return

-152.50%

ROIC

-161.90%

Interest Coverage

-1,138.20

Quick Ratio

4.20

Other Data

Shares on Issue (Fully Dilluted)

902m

HALO Sector

Healthcare

Next Company Report Date

29-Aug-24

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

BIT Announcements

Latest Announcements

Date Announcements

31 October 22

Letter to Shareholders

×

Letter to Shareholders

31 October 22

Commencement of Rights Trading - BITRC

×

Commencement of Rights Trading - BITRC

31 October 19

Presentation to Investors

×

Presentation to Investors

31 October 06

Anti-HCV Compound Presentation to International Conference

×

Anti-HCV Compound Presentation to International Conference

31 March 11

Presentation to Investors

×

Presentation to Investors

31 January 23

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

30 May 22

POSITIVE FDA GUIDANCE FOR COVID-19 CLINICAL PROGRAM

×

POSITIVE FDA GUIDANCE FOR COVID-19 CLINICAL PROGRAM

30 May 13

PRESENTATION OF HIV DATA AT INTERNATIONAL AIDS SOCIETY

×

PRESENTATION OF HIV DATA AT INTERNATIONAL AIDS SOCIETY

29 September 23

Response to ASX Price Query

×

Response to ASX Price Query

29 September 09

Annual Report and Notice of AGM

×

Annual Report and Notice of AGM

29 November 22

Change of Director's Interest Notice

×

Change of Director's Interest Notice

28 October 13

Biotron to Present at Australia Biotech Invest 2013

×

Biotron to Present at Australia Biotech Invest 2013

28 November 22

Notification of cessation of securities - BIT

×

Notification of cessation of securities - BIT

28 November 18

PRESENTATION OF BIT225-009 HIV-1 PHASE 2 DATA

×

PRESENTATION OF BIT225-009 HIV-1 PHASE 2 DATA

28 November 12

Chairman\'s Address and Presentation to the AGM

×

Chairman\'s Address and Presentation to the AGM

28 May 15

Presentation to Investors

×

Presentation to Investors

28 July 23

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

28 July 22

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

28 January 22

Quarterly Appendix 4C Cash Flow Report

×

Quarterly Appendix 4C Cash Flow Report

28 January 22

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

28 August 15

Annual Report to Shareholders

×

Annual Report to Shareholders

28 August 14

Annual Report to Shareholders

×

Annual Report to Shareholders

28 August 13

Annual Report to shareholders

×

Annual Report to shareholders

27 October 23

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

27 October 22

Proposed issue of securities - BIT

×

Proposed issue of securities - BIT

27 October 22

Renounceable Issue

×

Renounceable Issue

27 October 22

Prospectus

×

Prospectus

BIT Fundamentals

Per Share Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.00 -0.00 -0.00 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.00 -0.00 -0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock 17.0 13.6 -13.2 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.00 -0.00 -0.00 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.00 -0.00 -0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock 11.1 13.3 -3.7 Lock Lock Lock
     Yield % Lock Lock Lock Lock -10.3 -5.7 -15.4 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.01 0.00 0.00 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.01 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock -44.6 -71.7 133.4 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 725 725 821 Lock Lock Lock
Basic m Lock Lock Lock Lock 725 725 821 Lock Lock Lock

Financial Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 4 4 5 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock 5.6 4.4 4.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -4 -3 -5 Lock Lock Lock
     Growth % Lock Lock Lock Lock -6.8 36.0 -82.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -4 -3 -5 Lock Lock Lock
     Growth % Lock Lock Lock Lock -6.6 35.6 -81.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -5 -3 -5 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -1 0 -1 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -3 -3 -3 Lock Lock Lock
     Growth % Lock Lock Lock Lock 10.7 12.9 -25.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -3 -2 -3 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 0 0 6 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -3 -2 -3 Lock Lock Lock
     Growth % Lock Lock Lock Lock -10.8 28.6 -35.1 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 4 2 4 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 4 2 4 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -4 -2 -4 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 0 1 1 Lock Lock Lock
Equity $m Lock Lock Lock Lock 4 1 3 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 4 1 3 Lock Lock Lock
     Growth % Lock Lock Lock Lock -44.6 -70.6 180.0 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -73.8 -145.9 -84.5 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -82.7 -254.6 -110.1 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -79.3 -110.3 -229.7 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -58.9 -111.3 -161.9 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -62.9 -97.5 -152.5 Lock Lock Lock

Ratios Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock -3,385.9 -541.5 -1,138.2 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 1.0 0.6 0.8 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -108.8 -152.3 -124.2 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 9.4 2.3 4.2 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 9.4 2.3 4.2 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 98.8 98.8 98.8 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -755.2 -324.5 -344.2 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -73.8 -145.9 -84.5 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.1 1.7 1.3 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -82.7 -254.6 -110.1 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -82.7 -254.6 -110.1 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 1,728.2 1,811.4 2,510.3 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -1,728.2 -1,811.4 -2,510.3 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

0.00%

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

BIT Shortsell

Frequently Asked Questions

The current share price of Biotron Limited (BIT:ASX) is AU$0.089.
The 52-week high share price for Biotron Limited (BIT:ASX) is AU$0.12.
The 52-week low share price for Biotron Limited (BIT:ASX)? is AU$0.02.
Biotron Limited (BIT:ASX) does not pay a dividend.
Biotron Limited (BIT:ASX) does not pay a dividend.
Biotron Limited (BIT:ASX) has a franking level of 0%.
Biotron Limited (BIT:ASX) is classified in the Healthcare.
The current P/E ratio for Biotron Limited (BIT:ASX) is .
halo-logo-inverted-rgb@72ppi-1
Login
Products
Company
Important

Get the latest insights and hot tips delivered right to your inbox

Apple Store
Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.